Clinical trial locations
Gynaecological cancer patients are all managed within 34 Cancer Centres located across the UK. These centres are only likely to see 1-5 new patients per year with rare gynaecological cancers. The low numbers of these cancers means that no single doctor or centre in the UK (or internationally) can hope to gain sufficient experience to be able to confidently treat patients with these specific types of cancer. At present doctors base their treatment on discussions with more experienced colleagues, published case reports and common sense.
About the trial
The purpose of this study is to obtain more information about specific rare gynaecological cancers. Gynaecological oncology doctors have selected approximately 20 gynaecological cancers that are very uncommon (probably between 5 and 50 new cases in the UK per year per rare cancer type). The information from the study will help doctors to better understand how these rare cancers are diagnosed and managed at present so that in the future they can be more confident about what treatments to offer patients.
Information about the rare gynaecological cancer, and any other significant medical conditions, together with any treatments (now, and in the longer term) will be collected from the treating hospital and entered anonymously into the RaNGO database.
As it is very difficult to obtain blood or tissue samples from enough patients with rare cancers, it is hoped that patients in this study will agree to donate samples (from the biopsies or surgical procedures that they have already had for diagnosis or treatment) for future scientific research. Therefore participants will also be invited to anonymously donate tissue, blood and bodily fluid (if available) samples to RaNGO.
A RaNGO Tissue Bank has been created and is hosted at the Human Tissue Resource Centre based at St Bartholomew’s Hospital in London.
Who can take part?
This trial is for women diagnosed with the following rare gynaecological cancers:
Malignant germ cell tumours (dysgerminoma, yolk sac tumour, choriocarcinoma,
embryonal carcinoma, immature teratoma, malignant mixed germ cell tumour,
teratoma with secondary malignant transformation)
Mucinous ovarian cancers
Potentially malignant non-granulosa cell sex-cord stromal tumours
(Sertoli, Sertoli-Leydig, Leydig and steroid cell tumours; microcystic stromal tumours, sex-cord tumour with annular tubules [SCTAT])
Small Cell Carcinoma of Ovary, Hypercalcaemic Type (Malignant
rhabdoid tumour of the ovary)
Adult Granulosa Cell Tumour
Juvenile Granulosa Cell Tumour
Female adnexal tumour of probable Wolffian origin (FATWO)
Endometrial stromal sarcoma, low and high-grade
Undifferentiated uterine sarcoma
Leiomyosarcoma and smooth muscle tumour of uncertain
malignant potential (STUMP)
Uterine tumour resembling ovarian sex cord tumour (UTROSCT)
Neuroendocrine tumours (all WHO categories)
Unusual morphological subtypes of cervical adenocarcinoma
(gastric type, mesonephric, serous, clear cell, carcinosarcoma)
Adenoid basal and adenoid cystic carcinoma